Novartis considers selling, seperating some units, WSJ reports

While Novartis has one of the most diversified businesses in the industry, from drugs and vaccines to generics, animal health and eye care, new Chairman Joerg Reinhardt and CEO Joseph Jimenez are considering whether to sell or separate some of its disparate divisions, reports the Wall Street Journal.